全球HIV归因癌症负担:一项全球发病率分析
该全球发病率分析评估了2022年185个国家和地区9种与HIV感染因果相关的癌症负担,采用meta分析相对危险度与UNAIDS 2023 HIV患病率估算人群归因分数并应用于GLOBOCAN 2022。2022年全球0.4%癌症(81 300/1900万)归因于HIV,主要来自宫颈癌、卡波西肉瘤和非霍奇金淋巴瘤,57 300例(70.5%)发生在非洲。
要点
- 2022年全球0.4%癌症(81 300/1900万)归因于HIV。
- 57 300例(70.5%)HIV归因癌症发生在非洲,东部非洲33 800例、南部非洲14 000例。
- 南部非洲HIV归因癌症年龄标化发病率达27.6/10万,亚洲最低为0.2/10万。
核心结论
- HIV归因癌症的绝对和相对负担在全球存在差异,这些数据可用于区域特异性HIV防控规划与评估以及疫苗和筛查等癌症特异性干预,以减少HIV感染者的感染相关癌症负担。
研究设计与样本
- 全球发病率分析,评估9种被认为与HIV感染因果相关的癌症:卡波西肉瘤、非霍奇金淋巴瘤、霍奇金淋巴瘤以及宫颈癌、肛门癌、阴茎癌、外阴癌、阴道癌和结膜癌。
- 癌症特异性人群归因分数主要基于报告相对危险度的meta分析和UNAIDS 2023的HIV患病率估算,并应用于GLOBOCAN 2022的185个国家和地区 national 癌症发病率估计,计算HIV归因癌症的例数和年龄标化发病率。
主要发现
- 2022年全球0.4%癌症(81 300/1900万)估计归因于HIV,主要驱动为宫颈癌(n=30 500,HIV归因癌症特异性人群归因分数4.6%)、卡波西肉瘤(n=24 500,70.6%)和非霍奇金淋巴瘤(n=12 800,2.4%)。
- 81 300例HIV归因癌症中57 300例(70.5%)发生在非洲,尤其是东部非洲(33 800例[41.6%])和南部非洲(14 000例[17.2%]),在这些地区HIV是所有癌症中超过10%的原因。
- HIV归因癌症年龄标化发病率亚洲最低(0.2/10万),南部非洲达27.6/10万。
- 非洲HIV归因癌症中宫颈癌占40.8%(23 400/57 300例),而北美(200[5.0%]/4000例)和北欧与西欧(100[5.3%]/1900例)不足10%,这些地区肛门癌(900[22.5%]和500[26.3%]例)、卡波西肉瘤(900[22.5%]和500[26.3%]例)和非霍奇金淋巴瘤(1400[35.0%]和500[26.3%]例)更常见。
临床怎么用
- 作者认为这些数据可用于区域特异性HIV防控规划与评估以及疫苗和筛查等癌症特异性干预,以减少HIV感染者的感染相关癌症负担。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: People living with HIV are at increased risk of multiple infection-related cancers due to HIV-driven immunosuppression. However, the global burden of cancer attributable to HIV remains unestimated. We aimed to comprehensively estimate the global and regional cancer burden attributable to HIV in 2022, and to understand geographical disparities in this burden. METHODS: Nine cancer types considered causally linked to HIV infection were assessed in this worldwide incidence analysis: Kaposi sarcoma; non-Hodgkin lymphoma; Hodgkin lymphoma; and cervical, anal, penile, vulvar, vaginal, and conjunctival cancer. Cancer-specific population attributable fractions (PAFs) were calculated, primarily from meta-analyses reporting relative risks and HIV prevalence estimates sourced from UNAIDS 2023. PAFs were applied to national cancer incidence estimates from GLOBOCAN 2022 to estimate the numbers and age-standardised incidence rates (ASIRs) of HIV-attributable cancers for 185 countries and territories. FINDINGS: In 2022, 0·4% of global cancer cases (81 300 of 19 million) were estimated to be attributable to HIV, largely driven by cervical cancer (n=30 500, HIV-attributable cancer-specific PAF 4·6%), Kaposi sarcoma (n=24 500, 70·6%), and non-Hodgkin lymphoma (n=12 800, 2·4%). 57 300 (70·5%) of the 81 300 HIV-attributable cancer cases occurred in Africa, particularly in eastern (33 800 [41·6%] cases) and southern Africa (14 000 [17·2%] cases), where HIV was the cause of more than 10% of all cancers. ASIRs of HIV-attributable cancer were lowest in Asia (0·2 per 100 000) and reached 27·6 per 100 000 in southern Africa. The relative importance of HIV-attributable cancers varied globally, with cervical cancer accounting for 40·8% (23 400 of 57 300 cases) of HIV-attributable cancer in Africa, but less than 10% in North America (200 [5·0%] of 4000 cases) and in northern and western Europe (100 [5·3%] of 1900 cases), where anal cancer (900 [22·5%] and 500 [26·3%] cases), Kaposi sarcoma (900 [22·5%] and 500 [26·3%] cases), and non-Hodgkin lymphoma (1400 [35·0%] and 500 [26·3%] cases) were more common. INTERPRETATION: The absolute and relative HIV-attributable cancer burden varies globally. These data can inform region-specific planning and evaluation of HIV control, as well as cancer-specific interventions such as vaccination and screening, to reduce the infection-related cancer burden in people living with HIV. FUNDING: None.
引用
- Huang Y, Georges D, Rumgay H, et al. Global burden of cancer attributable to HIV: a worldwide incidence analysis. Lancet Glob Health. 2025. PMID: 40845879. doi:10.1016/S2214-109X(25)00264-5
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。